HBV and HCV infections in heart transplant recipients

Hepatitis C in the setting of kidney, heart, lung, and bone marrow transplants

“…In one study of 34 renal transplant recipients with HCV infection and serial biopsies obtained 4.5 ± 4.3 years after the initial biopsy, there was no morphologic change in follow-up specimens of patients with steatosis or chronic persistent hepatitis, but the majority of patients with hemosiderosis (66%) or early (60%) and advanced (100%) chronic active hepatitis showed a progression to liver cirrhosis [19]. In an 8-year retrospective study of 360 heart transplant patients with HCV infection, 58% had developed chronic liver disease, 17% of these patients developed cirrhosis, and 8% died of liver failure [6]. In 57 BMT patients with HCV infection, 22 with pretransplant HCV and 35 with posttransplant HCV, 10% did not develop liver disease, acute hepatitis was seen in 18% of patients, 39% had chronic hepatitis, and liver failure occurred in 33% [16].…”

“…Risk factors in renal transplant patients for HCV infection include race, geographic origin of recipient, type and duration of dialysis before transplantation, number of blood transfusions, history of previous transplants, and hepatitis B virus (HBV) infection [5]. The prevalence of HCV within heart transplant recipients is approximately 12% to 13% [6,7]. One retrospective study of 360 consecutive patients in Italy showed the overall prevalence of HCV in cardiac transplant patients to be 12.5%, but when further stratified, prevalence prior to 1990 was 28% and after 1990 it was 4.2%.…”

“…One retrospective study of 360 consecutive patients in Italy showed the overall prevalence of HCV in cardiac transplant patients to be 12.5%, but when further stratified, prevalence prior to 1990 was 28% and after 1990 it was 4.2%. This reflects the effectiveness of HCV donor and blood screening modalities instituted in the early 1990s [6]. With regard to BMT, the risk of being HCV RNA positive was clearly associated with previous history of blood transfusions [8].…”

Challenges in Long-Term Mechanical Circulatory Support and Biological Replacement of the Failing Heart

“…44 The prevalence of HCV among cardiac transplant recipients is reported as 12%, 45 but the breakdown of pretransplant infection compared with infection acquired during or after transplant is uncertain. Outcomes of HCV infection among HCVseropositive heart transplant recipients are also uncertain.…”

Effects of autoantibodies against β1-adrenoceptor in hepatitis virus myocarditis on action potential and L-type Ca2+currents

“…Many complications are considered to be involved in viral hepatitis [5][6][7][8][9][10][11][12][13][14][15][16][17] . Hepatitis virus myocarditis (HVM) as a consequence of hepatitis virus infection, secondary to Coxackie virus myocarditis in morbidity in hepatitis virus predominated areas of China, displays severe cardiac manifestations in addition to liver impairment [18] .…”